Advances in the biology and therapy of patients with chronic myeloid leukaemia

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 3, 2009, Pages 395-407

  Jabbour, Elias ^a   Fava, Carmen ^b   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronic myeloid leukemia; Kinase inhibitors; Management; T315I mutation

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; CYTARABINE; DANUSERTIB; DASATINIB; HOMOHARRINGTONINE; IDARUBICIN; IMATINIB; NILOTINIB; OMACETAXINE; PANOBINOSTAT; PEGINTERFERON ALPHA; PEPTIDE VACCINE; PHA 739538; PROTEIN KINASE INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG; VORINOSTAT; XL 228;

ABSENCE OF SIDE EFFECTS; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; COUGHING; CROSS TOLERANCE; CYTOPENIA; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; HUMAN; LEUKEMIA RELAPSE; LOW DRUG DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 71849103177     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.09.002     Document Type: Review

References (74)

1. Mughal T.I., and Goldman J.M. Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?. Front Biosci 11 (2006) 198-208
2. Hill J.M., and Meehan K.R. Chronic myelogenous leukemia. Curable with early diagnosis and treatment. Postgrad Med 106 (1999) 149-152 157-159
3. Faderl S., Talpaz M., Estrov Z., et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 131 (1999) 207-219
4. Pasternak G., Hochhaus A., Schultheis B., et al. Chronic myelogenous leukemia: molecular and cellular aspects. J Cancer Res Clin Oncol 124 (1998) 643-660
5. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
6. Deininger M.W., Goldman J.M., and Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 96 (2000) 3343-3356
7. Skorski T., Nieborowska-Skorska M., Wlodarski P., et al. Blastic transformation of p53-deficient bone marrow cells by p2lObcr/abl tyrosine kinase. Proc Natl Acad Sci USA 93 (1996) 13137-13142
8. Serrano M., Lee H., Chin L., et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85 (1996) 2737
9. Beck Z., Kiss A., Tóth F.D., et al. Alterations ofP53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk Lymphoma 38 (2000) 587-597
10. Sherr C., and McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2 (2002) 103-112
11. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
12. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 340 (1999) 1330-1340
13. Sessions J. Chronic myeloid leukemia in 2007. J Manag Care Pharm 13 (2007) 4-7
14. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
15. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541
16. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006) 2542-2551
17. National Comprehensive Cancer Network. NCCN: clinical practice guidelines in oncology. Chronic Myelogenous Leuk (2009). http://www.nccn.org/index.asp Version 1 www.nccn.org/index.asp
18. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
19. O'Brien S.G., Guilhot F., Goldman J.M., et al. International randomized study of Interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 112 (2008) 76
20. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8 (2007) 1018-1029
21. Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 (2006) 1767-1773
22. Quintás-Cardama A., Kantarjian H.M., and Cortes J.E. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16 (2009) 122-1231
23. Hamdan M.Y., Sanders L., Oliveria S., et al. Discontinuation and dose modification of imatinib in clinical practice. J Clin Oncol 25 (2007) 7045
24. Jabbour E., Cortes J.E., and Kantarjian H.M. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer 112 (2008) 2112-2118
25. Hughes T., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006) 28-37
26. Jabbour E., Cortes J., O'Brien S., et al. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma 7 (2007) S51-S57
27. Kantarjian H.M., Larson R.A., Guilhot F., et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115 (2009) 551-560
28. Jabbour E., Kantarjian H., O'Brien S., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 113 (2008) 2154-2160
29. Sprycel (dasatinib) [package insert]. 2007.
30. Dasatinib prescribing information, May 2008.
31. Hochhaus A., Kantarjian H.M., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309
32. Cervantes F., Baccarani M., Lipton J., et al. Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: A two-year update of the START-C study. Haematologica 93 (2008) 372
33. Rousselot P., Corm S., Paquette R., et al. Dasatinib compared with high-dose imatinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) after failure of standard-dose imatinib - A two-year update of the START-R study. Haematologica 93 (2008) 48
34. Shah N.P., Kim D.W., Kantarjian H.M., et al. Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034. J Clin Oncol 25 (2007) 358
35. Tasigna (nilotinib) [package insert]. 2007.
36. Kantarjian H.M., Giles F., Bhalla K.N., et al. Nilotinib in Chronic Myeloid Leukemia Patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 112 (2008) 1112
37. Jabbour E., Kantarjian H.M., Baccarani M., et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase (CML-CP) or accelerated phase (CML-AP). Blood 112 (2008) 1103
38. Cortes J.E., Baccarani M., Guilhot F., et al. A Phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study. Blood 112 (2008) 130-131
39. Baccarani M., Castagnetti F., Simonsson B., et al. Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): Results of an European LeukemiaNet prospective study comparing 400 mg and 800 mg front-line. Blood 112 (2008) 75
40. Cortes J., O'Brien S., Jones D., et al. Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood 112 (2008) 170
41. Rosti G., Castagnetti F., Poerio A., et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: Results of a phase 2 trial of the GIMEMA CML Working Party. Blood 112 (2008) 73-74
42. Cortes J., O'Brien S., Borthakur G., et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood 112 (2008) 74
43. Golas J.M., Arndt K., Etienne C., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63 (2003) 375-381
44. Cortes J., Kantarjian H.M., Kim D.W., et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. Blood 112 (2008) 1098
45. Craig A.R., Kantarjian H.M., Cortes J.E., et al. phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. J Clin Oncol 25 (2007) 368s (abstract # 7046)
46. + + Leukemias with either failure to multiple TKI therapies or with T315I mutation. Blood 112 (2008) 3232
47. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
48. Rahmani M., Nguyen T.K., Dent P., et al. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol 72 (2007) 788-795
49. Gontarewicz A., Balabanov S., Keller G., et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111 (2008) 4355-4364
50. Paquette R.L., Shah N.P., Sawyers C.L., et al. PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. [abstract]. Blood 110 (2007) 1030
51. Revill P., Mealy N., Serradell N., et al. Panobinostat. Histone deacetylase (HDAC) inhibitor, apoptosis inducer, oncolytic. Drugs Future 32 (2007) 315-322
52. Spencer A., Prince M., DeAngelo D.J., et al. Phase IA/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies. [abstract]. Blood 110 (2007) 907
53. Dai Y., Chen S., Venditti C.A., et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia (CML) cells sensitive and resistant to imatinib mesylate. [abstract]. Blood 110 (2007) 1041a
54. Fiskus W., Pranpat M., Bali P., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl expressing human leukemia cells. Blood 108 (2006) 645-652
55. Dasmahapatra G., Yerram N., Dai Y., et al. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res. 13 (2007) 4280-4290
56. Kadia T.M., Borthakur G., Wierda W., et al. A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia. [abstract]. J Clin Oncol 25 18S (2007) 7066
57. O'Brien S., Talpaz M., Cortes J., et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 94 (2002) 2024-2032
58. O'Brien S., Giles F., Talpaz M., et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98 (2003) 888-893
59. Cortes, Khoury H.J., Corm S., et al. Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation. [abstract]. J Clin Oncol 26 (2008) 7021
60. Bocchia M., Gentili S., Abruzzese E., et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365 (2005) 657-662
61. Kantarjian H.M., O'Brien S., Cortes J., et al. Results of decitabine (5′-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98 (2003) 522-528
62. Issa J.P., Gharibyan V., Cortes J., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23 (2005) 3948-3956
63. Guilhot F., Mahon F.-X., Guilhot J., et al. Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): first results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC). Blood (ASH Annual Meeting Abstracts) 112 (Nov 2008) 183
64. Hehlmann R., Saussele S., Lauseker M., et al. Randomized clinical trial for the optimization of imatinib therapy by combination, dose escalation and transplantation. Designed first interim analysis of the German CML study IV. Haematologica 94 Suppl. 2 (2009) 193 abs. 0478
65. Lee S.J., Kukreja M., Wang T., et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112 8 (2008 Oct 15) 3500-3507
66. Oehler V.G., Gooley T., Snyder D.S., et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 109 4 (2007 Feb 15) 1782-1789
67. Saussele S., Lauseker M., Gratwohl A., et al. Allogeneic hematopoietic stem cell transplantation (HSCT) in the imatinib-era: high survival rate following allogeneic HSCT after imatinib failure: results of the german CML study IV. Blood (ASH Annual Meeting Abstracts) 112 (Nov 2008) 448
68. Jabbour E., Cortes J., Kantarjian H.M., et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108 (2006) 1421-1423
69. Cortes J., Jabbour E., Kantarjian H., et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110 (2007) 4005-4011
70. Muller M.C., Cortes J., Kim D.W., et al. Dasatinib efficacy in patients with chronic myelogenous leukemia in chronic phase (CML-CP) and pre-existing BCR-ABL mutations. Blood 112 (2008) abstract 449
71. Hughes T., Saglio G., Branford S., et al. Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP). J Clin Oncol 27 25 (2009) 4204-4210
72. Jabbour E., Kantarjian H., Jones D., et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112 (2008) 53-55
73. Soverini S., Colarossi S., Gnani A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 12 (2006) 7374-7379
74. Jabbour E., kantarjian H.M., Jones D., et al. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112 (2008) 4839-4842